Novavax Covid-19 shot could be cleared for US use by May: CEO

Chief Executive Stanley Erck says talks with the US FDA are ongoing and the agency may require Novavax to submit data from its US trial, which could take an additional two months to complete, pushing back US clearance to mid-summer